ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,459.10
      1.11%
      US Tech 100
      18,514.00
      1.00%
      Dow Jones
      40,589.34
      1.64%
      Brent Oil
      79.745
      0.00%
      Bitcoin
      68,231.91
      0.47%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Lyell Immunopharma Inc (LYEL) Quote

      Lyell Immunopharma Inc

      Lyell Immunopharma Inc (LYEL)

      NASDAQ
      1.64
      0.01
      (0.61%)
      Closed July 27 4:00PM
      Delayed by 15 minutes
      1.64
      0.00
      (0.00%)
      After Hours: 5:59PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      1.64
      Bid
      1.54
      Ask
      2.20
      Volume
      372,722
      1.61 Day's Range 1.72
      1.18 52 Week Range 3.2556
      Market Cap
      418.1M
      Previous Close
      1.63
      Open
      1.69
      Last Trade
      50
      @
      1.68
      Last Trade Time
      Financial Volume
      $ 612,371
      VWAP
      1.643
      Average Volume (3m)
      969,683
      Shares Outstanding
      254,939,222
      Dividend Yield
      -
      PE Ratio
      -1.78
      Earnings Per Share (EPS)
      -0.92
      Revenue
      2.92M
      Net Profit
      -234.63M

      About Lyell Immunopharma Inc

      Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors). Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      lyell.com
      Headquarters
      Dover, Delaware, USA
      Founded
      1970
      Lyell Immunopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LYEL. The last closing price for Lyell Immunopharma was $1.63. Over the last year, Lyell Immunopharma shares have traded in a share price range of $ 1.18 to $ 3.2556.

      Lyell Immunopharma currently has 254,939,222 shares outstanding. The market capitalization of Lyell Immunopharma is $415.55 million. Lyell Immunopharma has a price to earnings ratio (PE ratio) of -1.78.

      LYEL Latest News

      More News

      Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

      Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date...

      June 26 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      June 14 2024
      Edgar (US Regulatory)

      Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

      June 03 2024
      GlobeNewswire Inc.

      Lyell Immunopharma to Participate in BofA Securities Health Care Conference

      SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

      May 07 2024
      GlobeNewswire Inc.

      Form 424B5 - Prospectus [Rule 424(b)(5)]

      May 06 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      May 06 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      May 06 2024
      Edgar (US Regulatory)

      Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

      Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from...

      May 06 2024
      GlobeNewswire Inc.

      Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

      SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

      March 05 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      February 28 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.01-0.6060606060611.651.7451.5155269671.62467387CS
      40.2114.68531468531.431.921.47218581.64494887CS
      12-0.8-32.78688524592.442.8751.189696831.9731105CS
      26-0.48-22.6415094342.123.25561.189271492.13069438CS
      52-1.34-44.9664429532.983.25561.189743672.04400747CS
      156-12.86-88.689655172414.519.841.189528144.31632663CS
      260-17.11-91.253333333318.7519.841.189416714.57823994CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      WINTWindtree Therapeutics Inc
      $ 8.24
      (150.46%)
      		48.57M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NBSTWNewbury Street Acquisition Corporation
      $ 0.1349
      (92.71%)
      		122.1k
      YIBOPlanet Image International Ltd
      $ 2.915
      (53.43%)
      		260.07k
      CREVCarbon Revolution Public Ltd
      $ 9.00
      (45.87%)
      		8.06M
      NMHINatures Miracle Holding Inc
      $ 0.2035
      (-48.06%)
      		7.69M
      TANHTantech Holdings Ltd
      $ 0.2585
      (-47.23%)
      		6.75M
      DXCMDexCom Inc
      $ 64.00
      (-40.66%)
      		53.92M
      PSIGPS International Group Ltd
      $ 1.42
      (-31.40%)
      		716.26k
      POAIPredictive Oncology Inc
      $ 1.36
      (-27.27%)
      		6.02M
      SLNASelina Hospitality PLC
      $ 0.0305
      (-18.88%)
      		408.61M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NVDANVIDIA Corporation
      $ 113.06
      (0.69%)
      		293.33M
      SQQQProShares UltraPro Short QQQ
      $ 9.10
      (-2.88%)
      		176.49M
      SGMOSangamo Therapeutics Inc
      $ 0.8612
      (28.15%)
      		123.71M

      LYEL Discussion

      View Posts
      jondoeuk jondoeuk 1 month ago
      (OT) Dr Restifo is Co-founder and Chief Scientist at Marble Therapeutics. From this: ''At Marble Therapeutics, he is working to figure out how to rewind the epigenetic clock on these cells, using any means possible. The company started out with a focus on skin rejuvenation, adds CEO Denitsa Milanova, but expanded to also work on adoptive cell therapy to prove their platform works.'' https://web.archive.org/web/20231218233715/https://www.nature.com/articles/d41573-023-00206-6

      They have a license for TIL plus a neoantigen vaccine https://www.federalregister.gov/documents/2024/02/07/2024-02491/prospective-grant-of-an-exclusive-patent-license-vaccine-augmented-adoptive-cell-therapy-for-the

      Preclinical data on the vaccine https://jitc.bmj.com/content/11/Suppl_1/A418
      🎯 1 👍️ 1
      glenn1919 glenn1919 3 months ago
      LYEL.....................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 4 months ago
      LYEL active in the Gaucho session

      👍️0
      jondoeuk jondoeuk 4 months ago
      Tempting but I will remain on the sidelines.
      👍️0
      Monksdream Monksdream 4 months ago
      LYEL under $3
      👍️0
      glenn1919 glenn1919 4 months ago
      LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
      👍️0
      jondoeuk jondoeuk 9 months ago
      They could be working on this https://ash.confex.com/ash/2023/webprogram/Paper182417.html
      👍️0
      jondoeuk jondoeuk 10 months ago
      Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750444/0/en/Lyell-Immunopharma-Announces-the-Acceptance-of-Six-Abstracts-for-Presentation-at-2023-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html
      👍️0
      Monksdream Monksdream 10 months ago
      LYEL new 52 week low
      👍️0
      jondoeuk jondoeuk 1 year ago
      LYL119 https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=13739
      👍️0
      jondoeuk jondoeuk 1 year ago
      Preclinical data from another group (LYL119 will be NR4A3-deficient) https://www.biorxiv.org/content/10.1101/2023.04.21.537841v1.full
      👍️0
      glenn1919 glenn1919 1 year ago
      LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
      👍️0
      jondoeuk jondoeuk 2 years ago
      The FDA has cleared an IND for LYL845. The PhI trial will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into NSCLC and CRC. Initial data presentation is expected in 2024.
      👍️0
      jondoeuk jondoeuk 2 years ago
      SITC titles

      NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo

      Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R™ technology, a programmable synthetic cell-signaling platform

      The Epi-R™ technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function

      The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity

      Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology
      👍️0
      NY1972 NY1972 2 years ago
      recent technical advances using culture conditions with IL-7/IL-15 and
      the addition of IL-21 may enhance the enrichment for TSCM cells
      in the final CART product (74–76), which can be further increased
      with the addition of drugs blocking T-cell differentiation, such as
      glycogen synthase-3 inhibitors (77). Nevertheless, robust clinical grade protocols for generating TSCM-enriched CART products
      have not been developed so far. Recently, a few CART19 clinical
      trials for DLBCL have been conducted in which CART products
      were manufactured from CD62L+ isolated T cells to generate
      cellular products enriched for TCM cells (21, 78); however, due to
      prolonged culture conditions, enrichment for TSCM and TCM
      subsets in the infused product could not be demonstrated

      https://www.frontiersin.org/articles/10.3389/fimmu.2022.904497/full
      👍️0
      jondoeuk jondoeuk 2 years ago
      The AEs from the LD chemo*. I expect more data (dose expansion is ongoing) from them at ASH. As for NVS, a pivotal trial is planned and DL2 (12.5M) is the recommended dose.

      * Some very early clinical data testing an anti-GD2 CAR-T with constitutive signaling from an engineered IL-7 receptor
      👍️0
      NY1972 NY1972 2 years ago
      Thanks for the link.
      Most commonly reported grade 3/4 AEs were neutrophil count decrease (6/9, 67%), anemia (5/9, 56%), thrombocytopenia (2/9,22%), platelet count decrease (2/9, 22%) and no infection was reported. Complete response rate(CRR) was 78%

      Compared to T-Charge
      http://www.koreabiomed.com/news/articleView.html?idxno=12767

      👍️0
      jondoeuk jondoeuk 2 years ago
      For Epi-R, they use media with high concentrations of potassium (as well as multiple cytokines). As for that, T-Charge or BE, I think a product with mostly ''stem-like'' cells and additional edits will be needed. But it doesn't have to be the latter, as shRNA can be used. Here are some clinical data on an anti-CD19 CAR-T with knock-down of both PD-1 and TIGIT https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7522
      👍️0
      NY1972 NY1972 2 years ago
      Which will perform better ? BE with 7,8 edits on many genes, Epi secret sauce
      or T-Charge which seems to add a CAR only to starting material in order to retain CD4/CD8 ratio.
      YTB323 CAR-T cell products generated via this novel expansionless manufacturing process retained the immunophenotype of the input leukapheresis materia
      👍️0
      jondoeuk jondoeuk 2 years ago
      That depends. Typically, the more the cells expand during manufacturing, the more they differentiate. In the case of ALLO, it seems most are effector memory (manufacturing time is ~19 days and there are a number of steps involved). LYEL refer to this as the expansion/quality paradox. With Epi-R, they have shown they can expand TCR-T cells up to 18 billion by day ten. In addition, these cells are over 94% viable and maintain their ''stem-like'' qualities.
      👍️0
      NY1972 NY1972 2 years ago
      Do you need Epigenetic Reprogramming if pts can be treated with healthy, young donor T cells?
      👍️0
      jondoeuk jondoeuk 2 years ago
      ISSCR poster https://ir.lyell.com/static-files/971404cb-28eb-46fc-839f-b20735899373
      👍️0
      jondoeuk jondoeuk 2 years ago
      Posters https://ir.lyell.com/static-files/d3a3d05c-1b39-4092-bf82-a486933bc268

      https://ir.lyell.com/static-files/6014be8d-4e9d-499b-a496-513d2962f3e4
      👍️0
      jondoeuk jondoeuk 2 years ago
      1115: Epigenetic Reprogramming (Epi-R™) Yields T-Cell Receptor Products with Improved Stemness, Metabolic Fitness, and Functional Activity in the Presence of Persistent Antigen Exposure https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=2014

      661: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1597
      👍️0
      jondoeuk jondoeuk 2 years ago
      GSK has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

      This uses Epi-R.
      👍️0
      jondoeuk jondoeuk 2 years ago
      AACR poster https://ir.lyell.com/static-files/ad2cd8dc-b41b-4536-a854-c4d1246422e6
      👍️0
      jondoeuk jondoeuk 2 years ago
      The PhI (n=54) of LYL797 has now been listed. The dose-escalation phase (TNBC only) will investigate four dose levels to determine the recommended RP2D. The dose expansion will enroll both TNBC and NSCLC.
      👍️0
      jondoeuk jondoeuk 3 years ago
      A new review https://www.sciencedirect.com/science/article/pii/S0952791521001278
      👍️0
      jondoeuk jondoeuk 3 years ago
      Morgan Stanley webcast https://morganstanley.webcasts.com/viewer/event.jsp?ei=1488969&tp_key=3cedc4a917
      👍️0
      jondoeuk jondoeuk 3 years ago
      New deck https://ir.lyell.com/static-files/96379999-4d8e-466b-a5d5-44f5f6f88583
      👍️0

      Your Recent History

      NASDAQ
      LYEL
      Lyell Immunopharma
      LSE
      0Y7Y
      Source S&p 500 Etf
      LSE
      GGP
      Greatland Gold
      BOV
      ITUBU356
      ITUBU356 Ex:33,96
      DBI
      3BWD
      DAXsector All Chemicals ...
      LSE
      0QE4
      Tryggingamidstodin Hf
      ASX
      QTM
      Quantum Health
      BIT
      F21572
      Vontobel Financial Produ...
      BIT
      F36790
      Vontobel Financial Produ...
      USOTC
      SMCE
      SMC Entertainment (PK)
      Delayed Upgrade Clock